The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
PD-L1 is a proven biomarker for patient response to KEYTRUDA® (pembrolizumab) in head and neck squamous cell carcinoma (HNSCC) (PD-L1 IHC 22C3 pharmDx [Instructions for Use], 2022). Review how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:
- Understand the core principles of PD-L1 pathology
- Learn the process for evaluating stained specimens for PD-L1 expression
- Recognize confounding considerations that affect PD-L1 interpretation
- Score images for PD-L1 expression across a variety of patient samples
For countries outside of the United States, see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy.